Grifols (GIFLF) Total Non-Current Liabilities (2009 - 2025)
Grifols' (GIFLF) quarterly Total Non-Current Liabilities came in at $40.7 million in Q4 2025, down 2.24% on a YoY basis from $41.7 million in Q4 2024, and down 2.24% quarter-over-quarter from $41.7 million in Q4 2024.
Analysis
Grifols (GIFLF) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Total Non-Current Liabilities for 17 consecutive years, with $40.7 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities fell 2.24% year-over-year to $40.7 million; the trailing twelve-month figure through Dec 2025 stood at $40.7 million (down 2.24% YoY), and the FY2025 full-year result was $39.5 million, down 29.39% from the prior year.
- Total Non-Current Liabilities declined to $40.7 million in Q4 2025 per GIFLF's latest filing, from $41.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $57.5 million in Q4 2022 and bottomed at $35.9 million in Q4 2021.
- Historically, Total Non-Current Liabilities has averaged $45.5 million across 5 years, with a median of $41.7 million in 2024.
- The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities soared 169.66% in 2021, then declined 18.98% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $35.9 million in 2021, then surged by 59.98% to $57.5 million in 2022, then declined by 10.51% to $51.4 million in 2023, then decreased by 18.98% to $41.7 million in 2024, then decreased by 2.24% to $40.7 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $40.7 million, $41.7 million, and $51.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 378.37 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 40.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 40.74 Mn |
| Dec 31, 2024 | 41.68 Mn |
| Dec 31, 2023 | 51.44 Mn |
| Dec 31, 2022 | 57.48 Mn |
| Dec 31, 2021 | 35.93 Mn |
| Dec 31, 2020 | 13.32 Mn |
| Sep 30, 2020 | 8.52 Bn |
| Mar 31, 2020 | 8.12 Bn |
| Dec 31, 2019 | 58.79 Mn |
| Sep 30, 2019 | 8.18 Bn |
| Dec 31, 2018 | 7.45 Bn |
| Sep 30, 2018 | 7.61 Bn |
| Jun 30, 2018 | 7.69 Bn |
| Mar 31, 2018 | 8.96 Bn |
| Dec 31, 2017 | 7.43 Bn |
| Jun 30, 2017 | 7.29 Bn |
| Dec 31, 2016 | 5.75 Bn |
| Sep 30, 2016 | 5.70 Bn |
| Jun 30, 2016 | 5.82 Bn |
| Mar 31, 2016 | 97.28 Mn |